Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells.
about
Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical reviewVitamin D in inflammatory diseases.Vitamin D receptor gene polymorphisms are associated with obesity and inflammosome activity.The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study.Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patientsParicalcitol reduces oxidative stress and inflammation in hemodialysis patients.Causes of Vitamin D Deficiency and Effect of Vitamin D Supplementation on Metabolic Complications in Obesity: a Review.Vitamin d receptor activators and clinical outcomes in chronic kidney disease.Calcium-Vitamin D Co-supplementation Affects Metabolic Profiles, but not Pregnancy Outcomes, in Healthy Pregnant WomenIncreased telomerase activity and vitamin D supplementation in overweight African AmericansAnti-Inflammatory Effects of Vitamin D on Human Immune Cells in the Context of Bacterial Infection.Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.Vitamin D: something new under the sun.Effects of Citral on Lipopolysaccharide-Induced Inflammation in Human Umbilical Vein Endothelial Cells.Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol.
P2860
Q26823927-99D93CA2-D7A1-4A8C-9BE9-F8D07CB13257Q33833563-81CCA004-684E-46BA-87FC-D2EA6E0B55F8Q33895584-F4D11E30-A2D3-4437-B7AE-0EB6EE51ECF7Q34059805-8933D7B8-029E-42FE-9E59-0EF57EA2DFF8Q34168451-9B456EAD-9F66-46B1-B1F9-2F200B0EBCBDQ34491713-489821F6-7A86-4AA6-9121-1EB17FB87E1DQ34493377-900F6248-315C-4A8B-93E4-7F3D1F114431Q35020986-483946C4-763B-4280-8CA3-85A9CB7323AEQ36733025-2B3471BC-11B9-40EF-901F-01C0D366258FQ37305594-C53D7C8B-A355-4487-A26E-2806A37FEEE8Q37535492-D636088C-8EAF-4B7D-8736-E18D4BC0F014Q37553481-EF1B8A13-60F8-4A42-8F84-88AAED7DF379Q39519961-F19C4EDA-EAF7-4CEA-B215-3A41DB924F8AQ40874383-7E98C5A5-A1FF-4563-A46F-0DE42548F246Q53840503-918BA35A-EC60-497A-80B3-5AF05DACB687
P2860
Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Paricalcitol reduces basal and ...... heral blood mononuclear cells.
@en
Paricalcitol reduces basal and lipopolysaccharide-induced
@nl
type
label
Paricalcitol reduces basal and ...... heral blood mononuclear cells.
@en
Paricalcitol reduces basal and lipopolysaccharide-induced
@nl
prefLabel
Paricalcitol reduces basal and ...... heral blood mononuclear cells.
@en
Paricalcitol reduces basal and lipopolysaccharide-induced
@nl
P2093
P1476
Paricalcitol reduces basal and ...... heral blood mononuclear cells.
@en
P2093
Charalambos Kartsios
Georgia Antoniadi
Grammati Galaktidou
Ioannis Stefanidis
Theodoros Eleftheriadis
P2860
P304
P356
10.1007/S11255-009-9541-1
P577
2009-03-04T00:00:00Z